CD274 and non-small cell lung carcinoma: This article reports clinical activity and manageable safety from an expansion cohort of patients with advanced non-small cell lung cancer that was primary refractory or had acquired resistance to anti-PD-(L)1 therapy from a phase I study of bintrafusp alfa.